Axcellerate Pharma deploys a unique combination of assets and operational capabilities to provide high quality CRO and CDMO services. Axcellerate Pharma is ideally positioned to accommodate drug product development activities as well as the manufacture of early cGMP clinical supplies of drug substance and sterile drug product for both large and small molecules. Axcellerate’s capabilities include a full complement of organic synthesis, analytical methods development and biological services. In addition, Axcellerate Pharma has dedicated process areas for biologics development, chemical development and sterile manufacturing of drug product including lyophilization.